SCHEMBL1521598

SCHEMBL1521598

CNc1ncc2c(n1)N(C(C)C)C(=O)N(c1cc(NC(=O)Nc3cc(C(C)(C)C)no3)c(F)cc1C)C2

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 6/20 0.42
RAF1 P04049 5/20 0.42
KRAS P01116 4/20 0.42
KDR P35968 4/20 0.42
MAP2K2 P36507 2/20 0.42
MAP2K1 Q02750 2/20 0.42
MAPK14 Q16539 7/20 0.39
MAPK13 O15264 3/20 0.38
ABL1 P00519 3/20 0.38
ALDH1A1 P00352 1/20 0.38
FYN P06241 1/20 0.36
ARAF P10398 1/20 0.36
SRC P12931 1/20 0.36
EPHA2 P29317 1/20 0.36
CSK P41240 1/20 0.36
MAPK8 P45983 1/20 0.36
MAPK9 P45984 1/20 0.36
IRAK1 P51617 1/20 0.36
MAPK12 P53778 1/20 0.36
MAPK10 P53779 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521733 0.91 ABL1 (0.45) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1521500 0.90 RAB9A (0.42) BRAFRAF1KRASKDRMAPK14
SCHEMBL1521858 0.89 BRAF (0.46) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1521552 0.88 BRAF (0.46) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1521732 0.87 BRAF (0.47) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1521665 0.85 ABL1 (0.48) KDRABL1SRCEPHB4BMX
SCHEMBL1521781 0.84 BRAF (0.46) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1522022 0.83 ABL1 (0.39) BRAFRAF1KRASKDRMAPK14
SCHEMBL1521679 0.82 BRAF (0.45) BRAFRAF1KRASKDRMAP2K2
SCHEMBL1521524 0.82 BRAF (0.43) BRAFRAF1KRASKDRMAP2K2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KRAS 30/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 BRAF 1/4885RAF1 3/4885KRAS 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.